Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Clin Ter ; 175(2): 83-91, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38571463

RESUMEN

Abstract: Virgin coconut oil (VCO) is a processed edible oil, which is removed from the mature coconuts. It is a colourless water insoluble liquid and obtained by the hot and cold extraction processes. The nutritional components of VCO are mainly contributed to by lauric acid, its primary content. VCO has shown its anticancer, antimicrobial, analgesic, antipyretic and antiinflammatory properties. Because of these medicinal properties, VCO has gained the wider attention among the medical field. Most evidently VCO has shown its potential antioxidant property, because of its phenolic compounds and medium chain fatty acids. It is one of the beneficial compounds used to prevent and treat the oxidative stress induced neurological disorders like stress, depression and Alzheimer's disease. Dietary supplementation of VCO is easy and economical and safer in daily life among all age groups. It is also beneficial for the cardiovascular, respiratory, dermatological, reproductive and bone health. It can also be applied to the skin as a moisturizer in the paediatric age group. Hence, exploration of antioxidant property as well as other beneficial effects of VCO in various health conditions will be valuable.


Asunto(s)
Aceite de Coco , Aceite de Coco/uso terapéutico , Humanos , Antioxidantes/uso terapéutico , Aceites de Plantas/uso terapéutico
2.
J Am Nutr Assoc ; 43(3): 244-251, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-37708389

RESUMEN

OBJECTIVE: Statin monotherapy for dyslipidemia is limited by adverse effects and limited effectiveness in certain subgroups like metabolic syndrome. Add-on therapy with an agent with a known safety profile may improve clinical outcomes, and virgin coconut oil (VCO) may be the candidate agent for improving the cardiometabolic profile. The present study was conducted to evaluate the effect of add-on VCO with atorvastatin in dyslipidemia in adults. METHODS: A randomized, double-blind clinical trial was conducted on 150 patients with dyslipidemia who were randomized into control and test groups. The control group received atorvastatin monotherapy, whereas the test group received add-on VCO with atorvastatin for 8 weeks. At baseline, demographic, clinical, and biochemical parameters were assessed and repeated after 8 weeks of therapy. The main outcome measures were lipid profile, cardiovascular risk indices, 10-year cardiovascular risk, body fat compositions, and thiobarbituric acid reactive substances (TBARS). RESULTS: The increase in HDL in the test group was significantly greater than in the control group (MD: 2.76; 95%CI: 2.43-3.08; p < 0.001). The changes in the atherogenic index (p = 0.003), coronary risk index (p < 0.001), cardiovascular risk index (p = 0.001), and TBARS (p < 0.001) were significantly greater in the test group. The decrease in LDL, total cholesterol and lipoprotein(a), were significantly higher in the control group. There were no significant differences between the groups with respect to the changes in triglyceride, VLDL, and 10-year cardiovascular risk. CONCLUSIONS: Add-on VCO (1000 mg/day) with atorvastatin (10 mg/day) can achieve a better clinical outcome in patients with dyslipidemia by increasing HDL and improving oxidative stress cardiovascular risk indices.


Asunto(s)
Aterosclerosis , Dislipidemias , Adulto , Humanos , Aceite de Coco/uso terapéutico , Atorvastatina/uso terapéutico , Sustancias Reactivas al Ácido Tiobarbitúrico , Dislipidemias/tratamiento farmacológico , Aterosclerosis/tratamiento farmacológico
3.
J Nutr Biochem ; 114: 109272, 2023 04.
Artículo en Inglés | MEDLINE | ID: mdl-36681309

RESUMEN

This study was designed to evaluate the long-term effects of Fructose (20%) feeding in rats, simulating metabolic syndrome (MetS), and the effects of coconut oil (C.O.) supplementation when administered in a MetS context. MetS is a cluster of systemic conditions that represent an increased chance of developing cardiovascular diseases and type 2 diabetes in the future. C.O. has been the target of media speculation, and recent studies report inconsistent results. C.O. improved glucose homeostasis and reduced fat accumulation in Fructose-fed rats while decreasing the levels of triglycerides (TGs) in the liver. C.O. supplementation also increased TGs levels and fructosamine in serum during MetS, possibly due to white adipose tissue breakdown and high fructose feeding. Pro-inflammatory cytokines IL-1ß and TNF-α were also increased in rats treated with Fructose and C.O. Oxidative stress marker nitrotyrosine is increased in fructose-fed animals, and C.O. treatment did not prevent this damage. No significant changes were observed in lipoperoxidation marker 4-Hydroxynonenal; however, fructose feeding increased total conjugated dienes and caused conjugated dienes to switch their conformation from cis-trans to trans-trans, which was not prevented by C.O. treatment. Potential benefits of C.O. have been reported with inconsistent results, and indeed we observed some benefits of C.O. supplementation in aiding weight loss, fat accumulation, and improving glucose homeostasis. Nonetheless, we also demonstrated that long-term C.O. supplementation could present some problematic effects with higher risk for individuals suffering MetS, including increased TGs and fructosamine levels and conformational changes in dienes.


Asunto(s)
Aceite de Coco , Suplementos Dietéticos , Síndrome Metabólico , Animales , Ratas , Glucemia/metabolismo , Aceite de Coco/farmacología , Aceite de Coco/uso terapéutico , Diabetes Mellitus Tipo 2/etiología , Diabetes Mellitus Tipo 2/metabolismo , Fructosamina/metabolismo , Fructosamina/farmacología , Fructosa/metabolismo , Glucosa/metabolismo , Homeostasis , Hígado/metabolismo , Síndrome Metabólico/dietoterapia , Síndrome Metabólico/metabolismo , Estrés Oxidativo , Ratas Wistar , Inflamación/dietoterapia , Inflamación/metabolismo
4.
Minerva Endocrinol (Torino) ; 48(1): 76-87, 2023 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-34786908

RESUMEN

INTRODUCTION: Due to the composition and biological properties of coconut oil, there is still considerable debate regarding potential benefits for the management of obesity, including the specific impact on body weight (BW) reduction. This systematic review and meta-analysis of clinical trials aims to assess the impact of coconut oil on BW reduction in comparison to other oils and fats. EVIDENCE ACQUISITION: The databases, PubMed®, Web of Science®, EMBASE®, and SciVerse Scopus® were systematically searched. A combination of medical subject headings and words linked to coconut oil and obesity parameters were utilized. Any clinical trials comparing coconut oil to any other form of oil or fat, with more than one month feeding period among adults were considered. EVIDENCE SYNTHESIS: From the 540 potentially relevant papers, 9 were included. The period of coconut oil intake varied from four to twelve weeks, apart from one long-term trial where coconut oil was consumed for two years. When compared to other oils and fats, coconut oil substantially decreased BW (N.=546), Body Mass Index (BMI) (N.=551), and percentage of fat mass (FM%) (N.=491) by 0.75 kg (P=0.04), 0.28 kg/m2 (P=0.03), and 0.35% (P=0.008), respectively. Coconut oil consumption did not result in any significant alteration in waist circumference (WC) (N.=385) (-0.61 cm; P=0.30), waist-to-hip ratio (WHR) (N.=330) (-0.01; P=0.39) and FM (N.=86) (-0.25 kg; P=0.29). CONCLUSIONS: Results indicate a small statistically significant reduction in BW, BMI, and FM% in the coconut oil group. In contrast, consumption of coconut oil had no statistically significant effect on WC, WHR, or FM.


Asunto(s)
Obesidad , Humanos , Aceite de Coco/uso terapéutico , Peso Corporal , Obesidad/tratamiento farmacológico , Índice de Masa Corporal , Relación Cintura-Cadera
5.
Int J Dent Hyg ; 21(1): 188-194, 2023 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-34124840

RESUMEN

OBJECTIVES: The aim of this study was to compare the plaque-inhibiting effects of oil pulling therapy with sesame oil or coconut oil using 4-day plaque regrowth study model. METHODS: This clinical observer-masked, randomized, crossover designed study involved 24 participants. The participants received professional prophylaxis in the preparatory period and after that subjects started to use the allocated mouthrinse (coconut oil or sesame oil). On day 5, periodontal clinical parameters including plaque index (PI), gingival index (GI), stain index (SI) and bleeding on probing (BOP) were recorded. Subjects underwent a 14-day wash out period and then used the other mouthrinse for 4 days. RESULTS: Oil pulling therapy with coconut oil or sesame oil exhibited similar plaque regrowth inhibition (PI = 1.60 ± 0.28 and 1.49 ± 0.22, for oil pulling with coconut oil and sesame oil, respectively) and tooth staining (SI = 0.20 ± 0.11 and 0.21 ± 0.09, for oil pulling with coconut oil and sesame oil, respectively.) In addition, GI and BOP were similar in both groups (GI = 0.61 ± 0.19 and 0.69 ± 0.16; BOP = 0.09 ± 0.24 and 0.03 ± 0.03 for oil pulling with coconut oil and sesame oil, respectively). CONCLUSIONS: Oil pulling therapy with coconut or sesame oil showed similar results in terms of plaque regrowth inhibition and tooth staining. According to the present results, both coconut oil and sesame oil can be used for oil pulling therapy with the aim of plaque regrowth inhibition.


Asunto(s)
Antiinfecciosos Locales , Placa Dental , Decoloración de Dientes , Humanos , Clorhexidina/uso terapéutico , Antiinfecciosos Locales/uso terapéutico , Aceite de Sésamo/uso terapéutico , Aceite de Coco/uso terapéutico , Antisépticos Bucales/uso terapéutico , Placa Dental/prevención & control , Placa Dental/tratamiento farmacológico , Índice de Placa Dental
6.
Lipids Health Dis ; 21(1): 83, 2022 Aug 31.
Artículo en Inglés | MEDLINE | ID: mdl-36045407

RESUMEN

BACKGROUND: Despite having a 92% concentration of saturated fatty acid composition, leading to an apparently unfavorable lipid profile, body weight and glycemic effect, coconut oil is consumed worldwide. Thus, we conducted an updated systematic review and meta-analysis of randomized clinical trials (RCTs) to analyze the effect of coconut oil intake on different cardiometabolic outcomes. METHODS: We searched Medline, Embase, and LILACS for RCTs conducted prior to April 2022. We included RCTs that compared effects of coconut oil intake with other substances on anthropometric and metabolic profiles in adults published in all languages, and excluded non-randomized trials and short follow-up studies. Risk of bias was assessed with the RoB 2 tool and certainty of evidence with GRADE. Where possible, we performed meta-analyses using a random-effects model. RESULTS: We included seven studies in the meta-analysis (n = 515; 50% females, follow up from 4 weeks to 2 years). The amount of coconut oil consumed varied and is expressed differently among studies: 12 to 30 ml of coconut oil/day (n = 5), as part of the amount of SFAs or total daily consumed fat (n = 1), a variation of 6 to 54.4 g/day (n = 5), or as part of the total caloric energy intake (15 to 21%) (n = 6). Coconut oil intake did not significantly decrease body weight (MD -0.24 kg, 95% CI -0.83 kg to 0.34 kg), waist circumference (MD -0.64 cm, 95% CI -1.69 cm to 0.41 cm), and % body fat (-0.10%, 95% CI -0.56% to 0.36%), low-density lipoprotein cholesterol (LDL-C) (MD -1.67 mg/dL, 95% CI -6.93 to 3.59 mg/dL), and triglyceride (TG) levels (MD -0.24 mg/dL, 95% CI -5.52 to 5.04 mg/dL). However, coconut oil intake was associated with a small increase in high-density lipoprotein cholesterol (HDL-C) (MD 3.28 mg/dL, 95% CI 0.66 to 5.90 mg/dL). Overall risk of bias was high, and certainty of evidence was very-low. Study limitations include the heterogeneity of intervention methods, in addition to small samples and short follow-ups, which undermine the effects of dietary intervention in metabolic parameters. CONCLUSIONS: Coconut oil intake revealed no clinically relevant improvement in lipid profile and body composition compared to other oils/fats. Strategies to advise the public on the consumption of other oils, not coconut oil, due to proven cardiometabolic benefits should be implemented. REGISTRATION: PROSPERO CRD42018081461.


Asunto(s)
Enfermedades Cardiovasculares , Grasas de la Dieta , Adulto , Peso Corporal , Enfermedades Cardiovasculares/tratamiento farmacológico , Enfermedades Cardiovasculares/prevención & control , HDL-Colesterol , Aceite de Coco/farmacología , Aceite de Coco/uso terapéutico , Grasas de la Dieta/farmacología , Femenino , Humanos , Masculino , Aceites de Plantas/farmacología , Aceites de Plantas/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto
7.
Int J Obes (Lond) ; 46(10): 1735-1741, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-35778479

RESUMEN

AIM: This study aimed to discover the effects of coconut oil intake and diet therapy on anthropometric measurements, biochemical findings and irisin levels in overweight individuals. MATERIALS AND METHODS: Overweight individuals (n = 44, 19-30 years) without any chronic disease were included. In this randomized controlled crossover study, the participants were divided into two groups (Group 1: 23 people, Group 2: 21 people). In the first phase, Group 1 received diet therapy to lose 0.5-1 kg of weight per week and 20 mL of coconut oil/day, while Group 2 only received diet therapy. In the second phase, Group 1 received diet therapy while Group 2 received diet therapy and 20 mL of coconut oil/day. Anthropometric measurements were taken four times. Irisin was measured four times by enzyme-linked immunosorbent (ELISA) method and other biochemical findings were measured twice. Statistical analysis was made on SPSS 20. RESULTS: The irisin level decreased significantly when the participants only took coconut oil (p ≤ 0.05). There was a significant decrease in the participants' body weight, body mass index (BMI) level and body fat percentage (p ≤ 0.01). Insulin, total cholesterol, low density lipoproteins (LDL) cholesterol, and triglyceride (TG) levels of all participants decreased significantly (p ≤ 0.05). There was no significant difference in irisin level due to body weight loss (p ≤ 0.05); coconut oil provided a significant decrease in irisin level (p ≤ 0.05). CONCLUSION: Diet therapy and weight loss did not have an effect on irisin level, but coconut oil alone was found to reduce irisin level. Coconut oil had no impact on anthropometric and biochemical findings.


Asunto(s)
Aceite de Coco , Fibronectinas , Sobrepeso , Pérdida de Peso , Adulto , Antropometría , Colesterol/sangre , Aceite de Coco/farmacología , Aceite de Coco/uso terapéutico , Estudios Cruzados , Fibronectinas/sangre , Humanos , Insulinas/sangre , Lipoproteínas LDL , Sobrepeso/dietoterapia , Sobrepeso/patología , Triglicéridos/sangre , Adulto Joven
8.
Clin Exp Dent Res ; 8(5): 1249-1258, 2022 10.
Artículo en Inglés | MEDLINE | ID: mdl-35856483

RESUMEN

OBJECTIVES: In our research, we evaluated the effect of coconut and sesame oils using the microneedling technique on gingival inflammation and plaque accumulation among patients with gingivitis by creating microholes in the gingiva to facilitate the concentration and entrance of the oils through gingival tissues. MATERIALS AND METHODS: Twenty-four patients with clinically diagnosed plaque-induced gingivitis were selected from Vision dental hospital, Riyadh, KSA, and assigned to one of three groups randomly; group A consisted of eight participants who were treated with dermapen and topical coconut oil, group B had eight participants who were treated with dermapen and topical sesame oil, and group C involved eight patients who received periodontal mechanical treatment only. Postintervention gingival status and plaque status for all participants were assessed using a modified average gingival index and a plaque index at Weeks 1, 2, and 4. RESULTS: Groups A and B experienced highly significant reductions in gingival indices, while group C showed reduced scores but was not significantly notable. On the contrary, the three studied groups exhibited no significant difference in the reduction of plaque indices when compared altogether. CONCLUSION: Our study demonstrated an effective novel technique that revealed a noticeable improvement in gingival status and a reduction in the average gingival index and plaque index.


Asunto(s)
Placa Dental , Gingivitis , Aceite de Coco/uso terapéutico , Cocos , Placa Dental/terapia , Gingivitis/terapia , Humanos , Inflamación , Aceite de Sésamo/uso terapéutico
9.
Niger J Physiol Sci ; 37(2): 225-233, 2022 Dec 31.
Artículo en Inglés | MEDLINE | ID: mdl-38243570

RESUMEN

The effect of virgin coconut oil (VCO) supplemented diet on sodium benzoate (SB) - induced neurotoxicity in male Wistar rats was investigated. Twenty (20) male Wistar rats weighing 160-180g were divided into four (4) groups: Control which received 1ml of normal saline, SB-treated; received 200 mg/kg b.w, SB + Low Dose VCO-treated (SB + 5% VCO mixed with 95g of rat chow), and SB + High Dose VCO-treated (SB+ 15% VCO mixed with 85g of rat chow). The brain was processed for NRF-2, NF-kB, and acetylcholine esterase (AchE) gene expression levels. Also, the blood sample was processed for assessment of superoxide dismutase (SOD), catalase (CAT), and IL1B levels. One-way ANOVA and Tukey post hoc tests were used to analyze data. SB-treated rats with no intervention showed anxiety-like behavior and impaired memory as depicted by a significant (p<0.0001) increase in anxiety index, increase in brain NF-KB, increase in serum IL1B and increase in AchE gene expression level, reduction in the recognition ratio, decreased spontaneous alternation performance, decreased CAT and SOD levels and decreased NRF-2 expression level when compared to other groups (especially control and SB + 5% VCO). VCO supplemented diet (both 5% and 15%) significantly (p<0.0001) increased the CAT and SOD levels, increased the NRF-2 gene expression level, and significantly (p <0.0001) decreased the IL1-B level. Moreover, 5% VCO significantly (p<0.0001) decreased the anxiety index, decreased AchE and NFkB gene expression levels, increased spontaneous alternation performance, and increased recognition ratio compared to 15% VCO. VCO shows a neuroprotective effect in attenuating cognitive impairment and anxiety-like behavior in SB-induced model by modulating oxidative stress and inflammatory pathways, and also enhancing cholinergic neurotransmission. Keywords: Virgin coconut oil; sodium benzoate; acetylcholinesterase; catalase; superoxide dismutase; oxidative stress.


Asunto(s)
Disfunción Cognitiva , Fármacos Neuroprotectores , Ratas , Masculino , Animales , Aceite de Coco/farmacología , Aceite de Coco/uso terapéutico , Acetilcolinesterasa/metabolismo , Fármacos Neuroprotectores/farmacología , Fármacos Neuroprotectores/uso terapéutico , Catalasa/metabolismo , Antioxidantes/farmacología , Antioxidantes/metabolismo , Ratas Wistar , Factor 2 Relacionado con NF-E2/genética , Factor 2 Relacionado con NF-E2/metabolismo , Benzoato de Sodio , FN-kappa B/metabolismo , Dieta , Superóxido Dismutasa/metabolismo , Disfunción Cognitiva/tratamiento farmacológico , Transducción de Señal
10.
Int J Mol Sci ; 22(22)2021 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-34830192

RESUMEN

Recently, type 2 diabetes mellitus (T2DM) has been reported to be strongly associated with Alzheimer's disease (AD). This is partly due to insulin resistance in the brain. Insulin signaling and the number of insulin receptors may decline in the brain of T2DM patients, resulting in impaired synaptic formation, neuronal plasticity, and mitochondrial metabolism. In AD patients, hypometabolism of glucose in the brain is observed before the onset of symptoms. Amyloid-ß accumulation, a main pathology of AD, also relates to impaired insulin action and glucose metabolism, although ketone metabolism is not affected. Therefore, the shift from glucose metabolism to ketone metabolism may be a reasonable pathway for neuronal protection. To promote ketone metabolism, medium-chain triglyceride (MCT) oil and a ketogenic diet could be introduced as an alternative source of energy in the brain of AD patients.


Asunto(s)
Enfermedad de Alzheimer/dietoterapia , Enfermedad de Alzheimer/epidemiología , Aceite de Coco/uso terapéutico , Diabetes Mellitus Tipo 2/dietoterapia , Diabetes Mellitus Tipo 2/epidemiología , Dieta Cetogénica/métodos , Aceite de Palma/uso terapéutico , Enfermedad de Alzheimer/metabolismo , Péptidos beta-Amiloides/metabolismo , Animales , Comorbilidad , Diabetes Mellitus Tipo 2/metabolismo , Metabolismo Energético , Glucosa/metabolismo , Humanos , Insulina/metabolismo , Resistencia a la Insulina , Cetonas/metabolismo
12.
Oxid Med Cell Longev ; 2020: 5148503, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32089769

RESUMEN

Asthma is a chronic inflammatory disease of the airways characterized by immune cell infiltrates, bronchial hyperresponsiveness, and declining lung function. Thus, the possible effects of virgin coconut oil on a chronic allergic lung inflammation model were evaluated. Morphology of lung and airway tissue exhibited peribronchial inflammatory infiltrate, epithelial hyperplasia, and smooth muscle thickening in guinea pigs submitted to ovalbumin sensitization, which were prevented by virgin coconut oil supplementation. Additionally, in animals with lung inflammation, trachea contracted in response to ovalbumin administration, showed a greater contractile response to carbachol (CCh) and histamine, and these responses were prevented by the virgin coconut oil supplementation. Apocynin, a NADPH oxidase inhibitor, did not reduce the potency of CCh, whereas tempol, a superoxide dismutase mimetic, reduced potency only in nonsensitized animals. Catalase reduced the CCh potency in nonsensitized animals and animals sensitized and treated with coconut oil, indicating the participation of superoxide anion and hydrogen peroxide in the hypercontractility, which was prevented by virgin coconut oil. In the presence of L-NAME, a nitric oxide synthase (NOS) inhibitor, the CCh curve remained unchanged in nonsensitized animals but had increased efficacy and potency in sensitized animals, indicating an inhibition of endothelial NOS but ineffective in inhibiting inducible NOS. In animals sensitized and treated with coconut oil, the CCh curve was not altered, indicating a reduction in the release of NO by inducible NOS. These data were confirmed by peribronchiolar expression analysis of iNOS. The antioxidant capacity was reduced in the lungs of animals with chronic allergic lung inflammation, which was reversed by the coconut oil, and confirmed by analysis of peribronchiolar 8-iso-PGF2α content. Therefore, the virgin coconut oil supplementation reverses peribronchial inflammatory infiltrate, epithelial hyperplasia, smooth muscle thickening, and hypercontractility through oxidative stress and its interactions with the NO pathway.


Asunto(s)
Antioxidantes/uso terapéutico , Hiperreactividad Bronquial/terapia , Aceite de Coco/uso terapéutico , Neumonía/terapia , Animales , Antioxidantes/farmacología , Enfermedad Crónica , Aceite de Coco/farmacología , Femenino , Cobayas , Masculino
13.
Circulation ; 141(10): 803-814, 2020 03 10.
Artículo en Inglés | MEDLINE | ID: mdl-31928080

RESUMEN

BACKGROUND: Coconut oil is high in saturated fat and may, therefore, raise serum cholesterol concentrations, but beneficial effects on other cardiovascular risk factors have also been suggested. Therefore, we conducted a systematic review of the effect of coconut oil consumption on blood lipids and other cardiovascular risk factors compared with other cooking oils using data from clinical trials. METHODS: We searched PubMed, SCOPUS, Cochrane Registry, and Web of Science through June 2019. We selected trials that compared the effects of coconut oil consumption with other fats that lasted at least 2 weeks. Two reviewers independently screened articles, extracted data, and assessed the study quality according to the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). The main outcomes included low-density lipoprotein cholesterol (LDL-cholesterol), high-density lipoprotein cholesterol (HDL-cholesterol), total cholesterol, triglycerides, measures of body fatness, markers of inflammation, and glycemia. Data were pooled using random-effects meta-analysis. RESULTS: 16 articles were included in the meta-analysis. Results were available from all trials on blood lipids, 8 trials on body weight, 5 trials on percentage body fat, 4 trials on waist circumference, 4 trials on fasting plasma glucose, and 5 trials on C-reactive protein. Coconut oil consumption significantly increased LDL-cholesterol by 10.47 mg/dL (95% CI: 3.01, 17.94; I2 = 84%, N=16) and HDL-cholesterol by 4.00 mg/dL (95% CI: 2.26, 5.73; I2 = 72%, N=16) as compared with nontropical vegetable oils. These effects remained significant after excluding nonrandomized trials, or trials of poor quality (Jadad score <3). Coconut oil consumption did not significantly affect markers of glycemia, inflammation, and adiposity as compared with nontropical vegetable oils. CONCLUSIONS: Coconut oil consumption results in significantly higher LDL-cholesterol than nontropical vegetable oils. This should inform choices about coconut oil consumption.


Asunto(s)
Enfermedades Cardiovasculares/prevención & control , Aceite de Coco/uso terapéutico , Grasas de la Dieta/uso terapéutico , Peso Corporal , Colesterol/sangre , Ensayos Clínicos como Asunto , Humanos , Metabolismo de los Lípidos , Lipoproteínas LDL/sangre , Aceites de Plantas/uso terapéutico
14.
J Trop Pediatr ; 66(2): 129-135, 2020 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-31257430

RESUMEN

BACKGROUND: Preterm constitutes a major part of neonatal mortality, particularly in India. Due to dermal immaturity, preterm neonates are susceptible to various complications like infection, hypothermia, etc. Emollient application is a traditional practice in our subcontinent. AIMS: To find out the efficacy of coconut oil application for skin maturity, prevention of sepsis, hypothermia and apnea, its effect on long-term neurodevelopment and adverse effect of it, if any. MATERIAL AND METHODS: A randomized controlled trial was conducted in the rural field practice area of Department of Community Medicine, Burdwan Medical College from March 2014 to August 2018. Preterm born in the study period was divided into Group A (received virgin coconut oil application) and Group B (received body massage without any application). Neonatal skin condition was assessed on 7th, 14th, 21st and 28th day of life. Neurodevelopmental status was assessed on 3rd, 6th and 12th months. RESULTS: A total of 2294 preterm were included in the study. Groups A and B consisted of 1146 and 1148 preterm infants, consecutively. Mean gestational age of the study population was 31.9 ± 3.4 weeks and 50.4% were male. Mean weight loss in first few days was less in group A but mean weight gain per day was higher in group B. Lesser incidences of hypothermia and apnea, and better skin maturity and neurodevelopmental outcome were noted in group A. No significant adverse effect was noted with coconut oil application. CONCLUSION: Use of coconut oil helps in dermal maturity and better neurodevelopmental outcome. Further studies are warranted for universal recommendation.


Asunto(s)
Apnea/prevención & control , Aceite de Coco/administración & dosificación , Emolientes/administración & dosificación , Hipotermia/prevención & control , Recien Nacido Prematuro , Sepsis/prevención & control , Piel/efectos de los fármacos , Administración Cutánea , Aceite de Coco/uso terapéutico , Emolientes/uso terapéutico , Femenino , Humanos , Cuidado del Lactante/métodos , Recién Nacido , Masculino , Evaluación de Resultado en la Atención de Salud , Población Rural
15.
Complement Ther Med ; 47: 102193, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31780023

RESUMEN

OBJECTIVES: The aim of this study was to evaluate the plaque-inhibiting effects of oil pulling using 4- day plaque regrowth study model compared to 0.2% chlorhexidine gluconate (CHX) containing mouthrinse. DESIGN: The study was an observer-masked, randomized, cross-over design clinical trial, involving 29 volunteers to compare 0.2% CHX and oil pulling therapy in a 4- day plaque regrowth model. After the preparatory period, in which the subjects received professional prophylaxis, the subjects commenced rinsing with their allocated rinsed. On day 5 plaque index (PI), gingival index (GI), stain index (SI), bleeding on probing (BOP) were recorded from the subjects. Each participant underwent a 14- day wash out period and then used the other mouthrinse for four days. RESULTS: Oil pulling therapy presented similar inhibitory activity on plaque regrowth compared with CHX (PI = 1.67 ±â€¯0.24, 1.61 ±â€¯0.20, respectively) with less staining (SI = 0.21 ±â€¯0.13, 0.47 ±â€¯0.27, respectively). In addition, GI and BOP was similar in both groups (p > 0.05). CONCLUSION: Oil pulling with coconut oil seems to have similar plaque inhibition activity as CHX. In addition it caused less tooth staining than CHX. These findings suggest that oil pulling therapy may be an alternative to CHX rinse.


Asunto(s)
Antiinfecciosos Locales/uso terapéutico , Clorhexidina/análogos & derivados , Aceite de Coco/uso terapéutico , Placa Dental/tratamiento farmacológico , Antisépticos Bucales/uso terapéutico , Adolescente , Adulto , Clorhexidina/uso terapéutico , Estudios Cruzados , Índice de Placa Dental , Femenino , Humanos , Masculino , Persona de Mediana Edad , Encuestas y Cuestionarios , Adulto Joven
16.
Eur J Pediatr ; 178(9): 1317-1324, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-31267223

RESUMEN

Preterm infants are at risk of increased trans-epidermal water loss and infections due to epidermal immaturity. The emollient and anti-infective properties of coconut oil make it a potentially beneficial topical agent for this population. We aimed to systematically review randomised trials assessing the effects of topical coconut oil in preterm infants. Medline, EMBASE, Cochrane Central Register of Controlled Trials and CINAHL were searched. Seven trials (n = 727 infants) were included. The majority of trials included relatively mature infants (gestation > 32 weeks, birth weight > 1200 g). The duration of intervention (5-31 days) and outcomes of interest varied among included studies. Meta-analysis using random effects model found significantly lower incidence of hospital-acquired blood stream infections (HABSI) in the coconut oil group (11/164 vs 32/166; relative risk 0.35, 95% confidence interval 0.18, 0.67, p = 0.001; I2 = 0%, two RCTs). Overall, infants in the coconut oil group had decreased water loss, decreased infection rates, better growth and skin condition. There were no significant adverse effects associated with coconut oil application. The overall quality of evidence was considered moderate for the outcome of HABSI and low for the outcome of physical growth based on GRADE guidelines.Conclusion: Topical coconut oil application to the skin may be beneficial in preterm infants, but the quality of evidence is low to moderate. Adequately powered randomised controlled trials, especially in very preterm (< 32 weeks) and extremely preterm (< 28 weeks) infants, are needed. What is Known: • Coconut oil has been used traditionally for topical application in terms of infants in Asian countries What is New: • This systematic review found that topical application of coconut oil may reduce the risk of infection and improve weight gain and skin condition in preterm infants. However, the quality of evidence was considered to be moderate to low based on GRADE guidelines.


Asunto(s)
Antiinfecciosos/uso terapéutico , Aceite de Coco/uso terapéutico , Deshidratación/prevención & control , Emolientes/uso terapéutico , Enfermedades del Prematuro/prevención & control , Sepsis Neonatal/prevención & control , Cuidados de la Piel/métodos , Administración Cutánea , Humanos , Recién Nacido , Recien Nacido Prematuro , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento , Aumento de Peso
17.
Cont Lens Anterior Eye ; 42(6): 652-657, 2019 12.
Artículo en Inglés | MEDLINE | ID: mdl-31239200

RESUMEN

PURPOSE: To investigate the effect of Blephadex™ Eyelid Wipes on Demodex mites, ocular microbiota, bacterial lipase, tear film characteristics and ocular comfort after one month of daily use. METHODS: Twenty subjects were randomly assigned to use the Blephadex™ Eyelid Wipes on either eye once daily for 30 days whilst the contralateral eye was left untreated in this observer-masked, within-subject study. Demodex count, eyelid bacterial colony count, Tearscope Plus non-invasive tear break up time (NITBUT), Lipiview® tear film lipid layer thickness and phenol red thread test tear volume were measured at baseline and 30 days. Bacterial lipase was quantified from single bacterial colonies using a glycerol monolaurate assay. Ocular comfort was assessed at both visits using the Ocular Surface Disease Index (OSDI) questionnaire and visual analogue scales (VAS) to capture monocular symptoms of itching, dryness and overall discomfort. RESULTS: Six males and 14 females, median age 63.5 (range 48-76) completed the study. A statistically significant reduction in Demodex count was observed in treated eyes only (median ±â€¯IQR: treated eyes 2 ±â€¯3 vs. 0 ±â€¯2, ANOVA p = 0.04). Bacterial colony count, lipase production, NITBUT, lipid layer thickness and tear volume remained unchanged (p > 0.05). Overall comfort improved over time in treated eyes only (15 ±â€¯32 vs. 10 ±â€¯16, p = 0.05). Dryness symptoms significantly reduced in both treated and untreated eyes (23 ±â€¯42 vs. 12 ±â€¯21 and 23 ±â€¯41 vs. 10 ±â€¯15, p = 0.02). The OSDI and ocular itch scores remained unchanged (p > 0.05). CONCLUSION: In this pilot study, no changes were observed in ocular microbiota, tear film characteristics or bacterial lipase in eyes treated with Blephadex™ Eyelid Wipes after one month of daily use in this normal healthy population. Although a statistically significant reduction in Demodex count was observed in treated eyes, overall numbers of Demodex were low. A parallel group, placebo-controlled, randomised clinical trial in a population with active blepharitis is warranted to further elucidate these preliminary findings.


Asunto(s)
Desinfección/instrumentación , Enfermedades de los Párpados/microbiología , Enfermedades de los Párpados/parasitología , Lipasa/metabolismo , Microbiota/efectos de los fármacos , Infestaciones por Ácaros/tratamiento farmacológico , Aceite de Árbol de Té/uso terapéutico , Anciano , Bacterias/enzimología , Aceite de Coco/uso terapéutico , Recuento de Colonia Microbiana , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Carga de Parásitos , Proyectos Piloto , Microscopía con Lámpara de Hendidura , Lágrimas/química
18.
Artículo en Inglés | MEDLINE | ID: mdl-30659555

RESUMEN

BACKGROUND: Research studies that holistically investigated the effect of administration of Virgin Coconut Oil (VCO) on diabetic humans or animals are limited in literature. OBJECTIVE: To investigate the effect of administration of VCO on lipid profile, markers of hepatic and renal dysfunction, and hepatic and renal antioxidant activities of alloxan induced diabetic rats. METHODS: Twenty-four male albino rats were used, and they were divided into four groups of six rats each. Group 1 (Normal Control, NC) received distilled water (1 mL/kg); Group 2 (VCO Control) received VCO (5 mL/kg); Group 3 (Diabetic Control, DC) received distilled water (1 mL/kg); Group 4 (Test Group, TG) received 5 ml/kg of VCO. RESULTS: There were no significant differences in blood glucose, body weights, relative liver weights, relative kidney weights, hepatic and renal Superoxide Dismutase (SOD) activities, Malondialdehyde (MDA), albumin, aspartate Amino Transaminase (AST), alanine Amino Transaminase (ALT), Alkaline Phosphatase (ALP), urea, creatinine, uric acid, total cholesterol, triacylglycerol, Very Low Density Lipoprotein cholesterol (VLDL) and Low Density Lipoprotein cholesterol (LDL) concentrations; significant increases in renal Glutathione (GSH), hepatic catalase, Glutathione Peroxidase (GPx) and GSH but significant reduction in renal GPx and catalase activities of VCO control group compared with NC group. There were significant increases in blood glucose, relative liver and kidney weights, hepatic GPx, hepatic and renal MDA concentration, ALP, AST, ALT, urea, creatinine, uric acid, triacylglycerol, total cholesterol, LDL and VLDL concentrations; and significant decreases in body weight, hepatic SOD and GSH activities and albumin concentration but no significant difference in hepatic catalase activity of DC group compared with NC group. Administration of VCO to diabetic rats positively modulated these parameters compared with the diabetic control. CONCLUSION: The study showed the potentials of VCO in the management of hyperlipidemia, renal and hepatic dysfunctions imposed by hyperglycemia and by oxidative stress in diabetic rats.


Asunto(s)
Antioxidantes/uso terapéutico , Aceite de Coco/uso terapéutico , Diabetes Mellitus Experimental/sangre , Diabetes Mellitus Experimental/tratamiento farmacológico , Riñón/metabolismo , Hígado/metabolismo , Aloxano , Animales , Antioxidantes/farmacología , Aceite de Coco/farmacología , Diabetes Mellitus Experimental/inducido químicamente , Riñón/efectos de los fármacos , Peroxidación de Lípido/efectos de los fármacos , Peroxidación de Lípido/fisiología , Lípidos/sangre , Hígado/efectos de los fármacos , Masculino , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología , Ratas
19.
J Nutr ; 148(10): 1556-1563, 2018 10 01.
Artículo en Inglés | MEDLINE | ID: mdl-30204921

RESUMEN

Background: Few trials have examined the effects of coconut oil consumption in comparison with polyunsaturated fatty acid-rich oils such as corn oil. Objective: This trial assessed the effects of consuming foods made with corn oil compared with coconut oil on lipids, glucose homeostasis, and inflammation. Methods: This was a preliminary randomized crossover study of men (n = 12) and women (n = 13) with a mean age of 45.2 y, mean body mass index (in kg/m2) of 27.7, fasting LDL cholesterol ≥115 mg/dL and <190 mg/dL, and triglycerides (TGs) ≤375 mg/dL. Subjects consumed muffins and rolls providing 4 tablespoons (∼54 g) per day of corn oil or coconut oil as part of their habitual diets for 4 wk, with a 3-wk washout between conditions. Fasting plasma lipids and high-sensitivity C-reactive protein (hs-CRP) and glucose metabolism were assessed via an intravenous glucose tolerance test at baseline and 15 and 29 d of treatment. Responses were compared between treatments by ANCOVA. Results: Median baseline concentrations of LDL cholesterol, non-HDL cholesterol, total cholesterol (total-C), HDL cholesterol, total-C:HDL cholesterol, and TGs were 123, 144, 188, 46.0, 4.21, and 92.5 mg/dL, respectively. Changes from baseline for corn oil and coconut oil conditions, respectively, were: LDL cholesterol (primary outcome; -2.7% compared with +4.6%), non-HDL cholesterol (-3.0% compared with +5.8%), total-C (-0.5% compared with +7.1%), HDL cholesterol (+5.4% compared with +6.5%), total-C:HDL cholesterol (-4.3% compared with -3.3%), and TGs (-2.1% compared with +6.0%). Non-HDL cholesterol responses were significantly different between corn and coconut oil conditions (P = 0.034); differences between conditions in total-C and LDL cholesterol approached significance (both P = 0.06). Responses for hs-CRP and carbohydrate homeostasis parameters did not differ significantly between diet conditions. Conclusions: When incorporated into the habitual diet, consumption of foods providing ∼54 g of corn oil/d produced a more favorable plasma lipid profile than did coconut oil in adults with elevated cholesterol. This trial was registered at clinicaltrials.gov as NCT03202654.


Asunto(s)
Colesterol/sangre , Aceite de Coco/farmacología , Aceite de Maíz/uso terapéutico , Grasas de la Dieta/uso terapéutico , Conducta Alimentaria , Hipercolesterolemia/dietoterapia , Triglicéridos/sangre , Adolescente , Adulto , Anciano , Análisis de Varianza , Pan/análisis , Proteína C-Reactiva/metabolismo , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Aceite de Coco/uso terapéutico , Cocos/química , Aceite de Maíz/farmacología , Estudios Cruzados , Dieta , Grasas de la Dieta/farmacología , Femenino , Humanos , Hipercolesterolemia/sangre , Masculino , Persona de Mediana Edad , Adulto Joven , Zea mays/química
20.
Nutrients ; 10(7)2018 Jul 20.
Artículo en Inglés | MEDLINE | ID: mdl-30037019

RESUMEN

Fatty acid (FA) composition is a determinant of the physiological effects of dietary oils. This study investigated the effects of vegetable oil supplementation with different FA compositions on anthropometric and biochemical parameters in obese women on a hypocaloric diet with lifestyle modifications. Seventy-five women (body mass index, BMI, 30⁻39.9kg/m²) were randomized based on 8-week oil supplementation into four experimental groups: the coconut oil group (CoG, n = 18), the safflower oil group (SafG, n = 19), the chia oil group (ChG, n = 19), and the soybean oil placebo group (PG, n = 19). Pre- and post-supplementation weight, anthropometric parameters, and body fat (%BF), and lean mass percentages (%LM) were evaluated, along with biochemical parameters related to lipid and glycidemic profiles. In the anthropometric evaluation, the CoG showed greater weight loss (Δ% = -8.54 ± 2.38), and reduced BMI (absolute variation, Δabs = -2.86 ± 0.79), waist circumference (Δabs = -6.61 ± 0.85), waist-to-height ratio (Δabs = -0.041 ± 0.006), conicity index (Δabs = -0.03 ± 0.016), and %BF (Δabs = -2.78 ± 0.46), but increased %LM (Δabs = 2.61 ± 1.40) (p < 0.001). Moreover, the CoG showed a higher reduction in biochemical parameters of glycemia (Δabs = -24.71 ± 8.13) and glycated hemoglobin (Δabs = -0.86 ± 0.28) (p < 0.001). The ChG showed a higher reduction in cholesterol (Δabs = -45.36 ± 0.94), low-density lipoprotein cholesterol (LDLc; Δabs = -42.53 ± 22.65), and triglycerides (Δabs = -49.74 ± 26.3), but an increase in high-density lipoprotein cholesterol (HDLc; abs = 3.73 ± 1.24, p = 0.007). Coconut oil had a more pronounced effect on abdominal adiposity and glycidic profile, whereas chia oil had a higher effect on improving the lipid profile. Indeed, supplementation with different fatty acid compositions resulted in specific responses.


Asunto(s)
Colesterol/sangre , Cocos/química , Dieta Reductora , Ácidos Grasos/farmacología , Obesidad/sangre , Aceites de Plantas/farmacología , Salvia/química , Tejido Adiposo/metabolismo , Adulto , Glucemia/metabolismo , Composición Corporal/efectos de los fármacos , Índice de Masa Corporal , Carthamus tinctorius/química , Aceite de Coco/metabolismo , Aceite de Coco/uso terapéutico , Grasas Insaturadas en la Dieta/sangre , Suplementos Dietéticos , Ácidos Grasos/sangre , Ácidos Grasos/uso terapéutico , Femenino , Humanos , Obesidad/dietoterapia , Obesidad Abdominal/sangre , Obesidad Abdominal/dietoterapia , Aceites de Plantas/química , Aceites de Plantas/metabolismo , Aceites de Plantas/uso terapéutico , Glycine max/química , Circunferencia de la Cintura , Pérdida de Peso/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...